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Background—Heart failure with preserved ejection fraction (HFPEF) is a common and increasing public health problem.
Myocardial fibrosis is a key pathological feature of HFPEF. Peripheral collagen markers may reflect this excess fibrosis;
however, the relation of these markers to prognosis in patients with HFPEF has not as yet been determined.
Methods and Results—This substudy of the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE)
trial measured plasma levels of procollagen type I amino-terminal peptide, procollagen type III amino-terminal peptide,
and osteopontin in 334 patients with HFPEF. Measurements were performed at baseline and 6 months after
randomization to placebo or irbesartan 300 mg/day. The relation of baseline collagen markers to the I-PRESERVE
primary end point (all-cause death and hospitalization for prespecified cardiovascular causes) was evaluated by single
and multivariable analysis. Similar evaluations were performed for all-cause death alone as well as heart failure events
(death or hospitalization because of heart failure). Increased plasma levels of collagen markers at baseline were associated
with increased frequency of the study primary end point for all collagen markers. For each 10-g/L increase in procollagen
type I amino-terminal peptide, the hazard ratio (HR) for the primary end point was 1.09 (95% CI, 1.052 to 1.13; P0.0001);
for each 10-g/L increase in procollagen type III amino-terminal peptide procollagen type I amino-terminal peptide, the HR
was 2.47 (95% CI, 0.97 to 6.33; P0.059); and for each 10-nmol/L increase in osteopontin, the HR was 1.084 (95% CI, 1.026
to 1.15; P0.004). No variable remained significant as an independent predictor when introduced into a multivariable model.
Both treatment groups tended to reduce collagen markers, with the reduction significantly greater for placebo versus irbesartan
for procollagen type III amino-terminal peptide only (P0.0185).
Conclusions—Increased peripheral collagen turnover markers were not independently associated with increased mortality
and cardiovascular hospitalization in an HFPEF population on multivariable analysis but were associated on
single-variable analysis. These findings provide some support to the hypothesis that pathological fibrosis in the heart,
and possibly the peripheral vasculature, may be contributory to adverse clinical outcomes in patients with HFPEF.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00095238.(Circ Heart Fail. 2011;4:561-568.)
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Heart failure with preserved ejection fraction (HFPEF) isa common and increasing public health problem.1 Its
prevalence appears to be similar to that of patients with heart
failure with reduced ejection fraction (HFREF). Furthermore,
long-term major clinical outcomes associated with HFPEF
are poor, although in general, they are slightly better than for
HFREF.2
Clinical Perspective on p 568
Unlike HFREF for which there are a number of known
therapeutic strategies available to ameliorate morbidity and
mortality, there is no therapy that has been demonstrated to be
beneficial in the management of patients with HFPEF. This
may relate in part to an incomplete understanding of the
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pathophysiology that underlies this condition. However, fac-
tors that appear to be contributory to this pathophysiology
include hypertension, coronary ischemia, and the cardiac
sequelae of diabetes mellitus (if present).1 A common patho-
physiological accompaniment of HFPEF associated with all
these underlying etiologies is the accumulation of extracellu-
lar matrix (ECM) material3 within the heart (myocardial
fibrosis). ECM accumulation is, in turn, believed to be a
major contributor to the impaired cardiac relaxation that is the
hallmark of this condition.4
Clinical evaluation of the presence and magnitude of ECM
accumulation in the heart is difficult. The gold standard for
such evaluation is myocardial biopsy, but even then, fibrosis
may be missed if it is patchy and nonhomogeneously distrib-
uted through the heart.5 Various imaging modalities have
been proposed5 in an attempt to quantitate pathological ECM
distribution, but these may suffer from methodological defi-
ciencies in identifying true pathological fibrosis.
The use of biochemical markers also have been attempted
in this regard. Peripheral markers of collagen turnover have
been studied extensively in conditions such as hypertension,
left ventricular hypertrophy, and HFREF.6–8 However, there
has been little evaluation9 of peripheral collagen markers in
patients with HFPEF despite the aforementioned importance
of this pathophysiological biomarker. In particular, the utility
of such markers in predicting major cardiovascular and
mortal events has as yet not been undertaken.
We therefore conducted a substudy within the Irbesartan
in Heart Failure With Preserved Systolic Function (I-
PRESERVE) trial10 in which patients with HFPEF were
randomized to the angiotensin receptor blocker irbesartan or
to placebo to evaluate the impact of an angiotensin receptor
blocker on peripheral collagen markers as well as the clinical
utility of these markers in predicting such events.
In this prespecified substudy, we hypothesized that (1)
irbesartan (through blockade of the profibrotic peptide angio-
tensin II) would reduce pathological fibrosis as reflected by
reductions in peripheral collagen turnover markers compared
with placebo and (2) plasma levels of 1 peripheral collagen
marker measured at baseline would be predictive of future
major cardiovascular events in an HFPEF population.
Methods
Patient Population
A subgroup of sites involved in the overall I-PRESERVE trial10 were
invited to contribute patients to the I-PRESERVE peripheral colla-
gen marker substudy; 334 patients with HFPEF subsequently were
recruited into this substudy. Of these, 313 patients had full baseline
and 6-month assessments.
Laboratory Evaluation
We evaluated 3 clinically relevant peripheral markers of collagen
turnover: procollagen type I amino-terminal peptide (PINP), procol-
lagen type III amino-terminal peptide (PIIINP), and osteopontin.
Regarding preanalytical handling of blood samples, blood was spun
at 1800 rpm in a cold (4°C) centrifuge and plasma was extracted and
stored frozen at20°C for transfer to the laboratory on dry ice. PINP
was measured by electroluminescence assay on the Cobas E170
analyzer (Roche Diagnostics, Castel Hill, NSW, Australia), PIIINP
was measured by radioimmunoassay (Orion Diagnostica; Espoo,
Finland), and osteopontin by enzyme-linked immunosorbent assay
(IBL International; Hamburg, Germany). Intraassay and interassay
coefficients of variability were 10% for all 3 biomarkers.
Study Design
Plasma levels of PINP, PIIINP, and osteopontin were measured at
baseline and 6 months. Baseline measures were used to determine
the utility of such peripheral collagen markers in predicting major
events. These events comprised the main study’s primary end point
of being a composite of all-cause mortality and cardiovascular
hospitalization (time to first event), all-cause mortality alone, and a
heart failure composite comprising death of heart failure and
hospitalization for heart failure. All clinical events were evaluated at
the end of the study. Changes in collagen markers between baseline
and 6 months were used to evaluate the impact of irbesartan versus
placebo on levels of such markers.
Statistical Analysis and Sample Size
The sample size for this substudy was based on the RALES
(Randomized Aldactone Evaluation Study) collagen substudy, as-
suming that similar findings would be observed in this HFPEF
population with irbesartan versus placebo as with spironolactone
versus placebo in RALES.8 In the RALES study of advanced
HFREF, a significant reduction in plasma collagen markers was
observed with the aldosterone antagonist spironolactone versus
placebo in a sample of 261 patients.8 With an SD of 6% in
measurement of PINP, clinically relevant difference of 20% 0.05,
and power of 80%, a minimum of 120 patients were required in each
group to allow for dropouts. A minimum of 300 patients were,
therefore, recruited.
Multiple linear regression analysis was performed to evaluate
which baseline variables were independently associated with base-
line plasma collagen markers. The following variables were included
in the analysis: age, sex, New York Heart Association functional
class, systolic blood pressure, hemoglobin level, estimated glomer-
ular filtration rate, left ventricular ejection fraction, ischemic etiol-
ogy, hypertension etiology, history of atrial fibrillation, history of
diabetes, history of hospitalization in the previous 6 months, albumin
level, neutrophils, pulmonary congestion on chest radiograph, his-
tory of chronic obstructive pulmonary disease, heart rate, body mass
index, and serum sodium. Cox proportional hazards regression
models were used to assess the association between baseline plasma
collagen markers and time to the primary end point and the 2
secondary end points of time to all-cause mortality and time to the
heart failure composite end point. PINP was evaluated per 10-g/L
increase, PIIINP per 10-g/L increase, and osteopontin per 10-
nmol/L increase. Three models were evaluated for each end point.
First, each marker was tested alone in a univariable analysis. A
multivariable model then was tested that included the aforemen-
tioned 19 variables (model 1). Model 2 was model 1 plus plasma
level of N-terminal pro-brain natriuretic peptide. The planned sample
size for this substudy based on the first hypothesis to be tested (effect
of irbesartan versus placebo on change in collagen biomarker levels)
is likely underpowered in the evaluation of the second hypothesis to
be tested (relation of baseline plasma levels of peripheral collagen
markers to future major cardiovascular events).
Results
Study Patients
Baseline characteristics of the patients enrolled in the main
I-PRESERVE study according to treatment received as well
as the collagen substudy population of 313 patients are
summarized in Table 1. Mean exposure to therapy in both the
main I-PRESERVE study and the collagen substudy was
similar at 49.5 months.
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Table 1. Baseline Characteristics of Patients in the Entire Cohort and Collagen Substudy by Treatment
Entire Study Collagen Substudy
Characteristic Placebo (n2061) Irbesartan (n2067) Placebo (n164) Irbesartan (n149)
Demographic
Age, y 727 727 727 727
Age 75 y 716 (35) 697 (34) 63 (37) 61 (36)
Female sex 1264 (61) 1227 (59) 106 (62) 101 (60)
Race
White 1925 (93) 1934 (94) 153 (93) 136 (91)
Nonwhite 136 (7) 133 (6) 12 (7) 16 (10)
Clinical
NYHA class
II 444 (22) 426 (21) 39 (23) 40 (24)
III 1562 (76) 1582 (77) 131 (77) 126 (75)
IV 53 (3) 59 (3) 1 (0.6) 2 (1.2)
Systolic BP, mm Hg 13615 13715 13615 13617
Diastolic BP, mm Hg 799 799 799 7810
Heart rate, beats/min 7110 7211 7110 7110
Hemoglobin, g/dL 13.91.9 13.913.9 13.91.9 13.81.9
eGFR, mL/min per 1.73 m2 7222 7323 7525 7324
Serum sodium, mmol/L 1403 1403 1393 1392
Ejection fraction, % 609 599 619 5910
Cause of HF
Ischemia 500 (24) 536 (26) 40 (23) 41 (24)
Hypertension 1304 (63) 1318 (64) 119 (70) 105 (63)
Hospitalization for HF* 906 (44) 910 (44) 56 (32) 56 (33)
Medical history
Hypertension 1816 (88) 1834 (89) 156 (91) 145 (86)
Myocardial infarction 482 (23) 487 (24) 33 (19) 33 (20)
PCI or CABG 267 (13) 281 (14) 25 (15) 35 (21)
Atrial fibrillation 603 (29) 606 (29) 49 (29) 49 (29)
Diabetes mellitus 564 (27) 570 (28) 59 (35) 48 (29)
Stroke or TIA 201 (10) 198 (10) 20 (12) 17 (10)
Quality of life 4220 4221 3919 3821
Median NT-proBNP, pg/mL 320 (131–946) 360 (139–987) 382 (131–1096) 392 (115–978)
Medication
Diuretic 1675 (84) 1648 (83) 130 (77) 124 (77)
Loop 1041 (52) 1038 (52) 67 (39) 75 (46)
Thiazide 779 (38) 776 (38) 55 (32) 48 (30)
Spironolactone 309 (16) 312 (16) 24 (14) 24 (15)
ACE inhibitor 510 (25) 538 (26) 68 (40) 51 (32)
Digoxin 269 (13) 291 (14) 12 (7) 23 (14)
-blocker 1169 (59) 1191 (60) 90 (53) 91 (56)
Calcium-channel blocker 787 (39) 802 (40) 70 (41) 56 (35)
Nitrate 534 (27) 539 (27) 27 (16) 29 (18)
Data are presented as meanSD, n (%), or median (interquartile range). ACE indicates angiotensin-converting enzyme; BP, blood
pressure; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; HF, heart failure; NT-proBNP, N-terminal
pro-brain natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; TIA, transient ischemic
attack.
*Within previous 6 months.
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Baseline Collagen Marker Levels and
Clinical Correlates
The median plasma level of PINP at baseline was 43.8 g/L
(Q1 to Q3, 28.9 to 63.5 g/L; minimum to maximum, 7.1 to
350 g/L; n333). The reference range for plasma PINP is
premenopausal women, 59 g/L; postmenopausal women,
76 g/L; men aged 25 to 70 years, 15 to 80 g/L; and men
aged70 years,80 g/L. Baseline variables independently
associated with baseline plasma PINP were baseline esti-
mated glomerular filtration rate, history of heart failure, and
history of atrial fibrillation.
The median plasma level of PIIINP at baseline was 4.3
g/L (Q1 to Q3, 3.68 to 5.4 g/L; minimum to maximum, 1
to 20 g/L; n334). The reference range for plasma PIIINP
is 2.3 to 6.4 g/L in adults aged 19 to 65 years. Baseline
variables independently associated with baseline plasma
PINP were age, baseline estimated glomerular filtration rate,
baseline body mass index, and history of diabetes mellitus.
The median plasma level of osteopontin was 23 nmol/L
(Q1 to Q3, 10.14 to 47.4 nmol/L; minimum to maximum, 5 to
262 nmol/L; n317). No reference range for plasma osteo-
pontin has as yet been established. Baseline variables inde-
pendently associated with baseline plasma PINP were male
sex, age, baseline estimated glomerular filtration rate, ische-
mic etiology, history of atrial fibrillation, and etiology of
hypertension. All baseline collagen markers were strongly
positively correlated with baseline plasma N-terminal pro-
brain natriuretic peptide levels (r0.392 to 0.616, P0.001
to 0.008).
Relation of Collagen Markers to Major
Cardiovascular Events
Baseline Plasma Collagen Marker Levels
Increased plasma levels of collagen markers at baseline were
associated with increased frequency of key study end points
on single variable analysis (Tables 2 through 4). For baseline
osteopontin levels, there was a significant association with
the primary I-PRESERVE end point of all-cause mortality
and a borderline association with heart failure composite
Table 2. Primary End Point of All-Cause Mortality and HF Composite Event in Relation to
Baseline OPN Levels
No. Patients No. Events % Events HR 95% CI P
Primary end point
OPN alone (per 10 nmol/L) 317 94 29.6 1.08 1.03–1.15 0.004
Model 1 plus OPN 274 81 29.5 0.98 0.92–1.06 0.653
Model 2 plus OPN 246 75 30.5 0.97 0.90–1.05 0.45
All-cause mortality
OPN alone (per 10 nmol/L) 317 49 15.4 1.06 1.02–1.11 0.007
Model 1 plus OPN 274 42 15.3 1.02 0.92–1.13 0.71
Model 2 plus OPN 246 39 15.8 0.99 0.88–1.11 0.823
HF composite events
OPN alone (per 10 nmol/L) 317 42 13.3 1.06 0.99–1.14 0.083
Model 1 plus OPN 274 37 13.5 0.99 0.89–1.09 0.839
Model 2 plus OPN 246 34 13.8 0.93 0.83–1.05 0.244
HR, hazard ratio; OPN, osteopontin. Other abbreviation as in Table 1.
Table 3. Primary End Point of All-Cause Mortality and HF Composite Event in Relation to
Baseline PINP Levels
No. Patients No. Events % Events HR 95% CI P
Primary end point
PINP alone 10 g/L 333 101 30.3 1.09 1.05–1.13 0.0001
Model 1 plus PINP 287 85 29.6 1.001 0.96–1.05 0.98
Model 2 plus PINP 257 78 30.3 0.99 0.95–1.04 0.637
All-cause mortality
PINP alone 10 g/L 333 52 15.6 1.06 1.03–1.09 0.001
Model 1 plus PINP 287 44 15.3 1.04 0.98–1.10 0.24
Model 2 plus PINP 257 40 15.5 1.03 0.96–1.10 0.43
HF composite events
PINP alone 10 g/L 333 46 13.8 1.09 1.05–1.13 0.0001
Model 1 plus PINP 287 39 13.5 1.03 0.97–1.1 0.275
Model 2 plus PINP 257 36 14 1.02 0.96–1.09 0.526
PINP indicates procollagen type I amino-terminal peptide. Other abbreviations as in Tables 1 and 2.
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events. For PINP baseline levels, all major end points were
highly significant. For baseline PIIINP, the primary end point
was borderline significant, whereas all-cause mortality and
heart failure composite events were highly significant. In
contrast, none of these markers remained significant predic-
tors of future events when entered into the 2 multivariable
models.
Change in Collagen Marker Levels
Change in collagen marker over the 6 months of the study and
its relation to subsequent cardiac events and death were
nonsignificant overall. One exception was the change in
osteopontin (P0.019), which was predictive for all-cause
mortality.
Kaplan–Meier plots of collagen markers (split along the median)
in relation to the primary study end point (all-cause death and
cardiovascular hospitalization) are shown in Figures 1 through 3
(PINP, PIIINP, and osteopontin, respectively).
Relation of Treatment to Collagen Marker Levels
After 6 months, treatment collagen markers tended to fall in both
the placebo and irbesartan groups (PINP,3.21.9 versus0.7
2.0 g/L, P not significant; PIIINP, 0.40.1 versus 0.10.1
g/L, P0.0185; osteopontin,5.62.1 versus3.62.2 ng/mL,
P not significant).
Discussion
The present analyses demonstrate that peripheral collagen
markers, when measured at baseline, are predictive of major
cardiovascular events in an HFPEF population. Specifically,
we observed that when baseline markers were split along the
median (irrespective of subsequent treatment received), there
was a significant increase in both time to all-cause death or
adjudicated protocol-specified cardiovascular hospitalization
(the main I-PRESERVE study primary end point), all-cause
death alone, and the heart failure composite end point on
single-variable analysis. These findings do not remain signif-
Table 4. Primary End Point of All-Cause Mortality and HF Composite Event in Relation to
Baseline PIIINP Levels
No. Patients No. Events % Events HR 95% CI P
Primary end point
PIIINP alone 10 g/L 334 102 30.5 2.47 0.97–6.33 0.059
Model 1 plus PIIINP 287 86 29.9 1.06 0.37–3.02 0.912
Model 2 plus PIIINP 259 80 30.8 0.84 0.27–2.62 0.764
All-cause mortality
PIIINP alone 10 g/L 334 52 15.6 2.85 1.52–5.36 0.001
Model 1 plus PIIINP 287 44 15.3 0.99 0.193–5.14 0.998
Model 2 plus PIIINP 259 40 15.4 0.80 0.13–4.92 0.813
HF composite events
P3NP alone 10 g/L 334 48 16.8 5.91 2.94–11.88 0.0001
Model 1 plus PIIINP 287 41 14.2 2.67 0.69–10.32 0.156
Model 2 plus PIIINP 259 38 14.6 1.70 0.39–7.42 0.479
PIIINP indicates procollagen type III amino-terminal peptide. Other abbreviations as in Tables 1 and 2.
Figure 1. Kaplan–Meier plot by baseline procolla-
gen type I amino-terminal peptide for time to all-
cause death or adjudicated protocol-specified car-
diovascular hospitalization. HR indicates hazard
ratio.
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icant, however, after adjustment for relevant baseline covari-
ates in a multivariable model. The present findings, therefore,
potentially support ECM accumulation (fibrosis) as being
pathophysiologically important in the progression of the
HFPEF disease process as well as being a contributor to
subsequent events.
These findings also somewhat mirror observations made in
patients with HFREF. Specifically, the RALES study of
patients with advanced HFREF observed that PIIINP was
found to be predictive of subsequent mortality in those
patients.8 In addition to traditional fibrosis markers such as
the amino-terminal peptides, which have been explored
extensively in HFREF and post-myocardial infarction left
ventricular systolic dysfunction settings, osteopontin was
assessed because it integrates both the inflammatory and the
fibrotic aspects of the cardiac remodeling process and appears
to be responsive to therapeutic interventions that meaning-
fully affect the cardiac remodeling process.11,12
Although plasma levels of collagen markers generally were
lowered by 6 months of irbesartan therapy, these reductions
were not large, generally not different from placebo, and
certainly not clinically significant. These findings are in
keeping with the overall I-PRESERVE study findings13
where irbesartan therapy did not affect either the primary end
point (all-cause mortality or cardiovascular hospitalization)
or the all-cause mortality alone end point. The absence of
impact of an angiotensin II AT1 receptor antagonist on
fibrosis markers is surprising because angiotensin II is a
well-established profibrotic stimulus in various experimental
settings, such as cardiac fibroblast cell culture.14 One possi-
bility is that the follow-up fibrotic marker assessment was not
of sufficient duration to meaningfully lower plasma levels.
For example, in the study of Mak et al,15 PIIINP levels were
lowered versus placebo at 12 months but not at 6 months.
Despite the limited nature of the relationships observed, it
may be speculated from the present findings that therapies
that beneficially affect pathological ECM deposition in pa-
tients with HFPEF may reduce major events in this popula-
tion. This is of considerable relevance because there have
been as yet no therapies proven to be of benefit in this
Figure 2. Kaplan–Meier plot by baseline procolla-
gen type III amino-terminal peptide for time to all-
cause death or adjudicated protocol-specified car-
diovascular hospitalization. Abbreviation as in
Figure 1.
Figure 3. Kaplan–Meier plot by baseline osteopon-
tin for time to all-cause death or adjudicated
protocol-specified cardiovascular hospitalization.
Abbreviation as in Figure 1.
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condition. A number of direct antifibrotic pharmacological
agents have been developed; the present findings in an
HFPEF population suggest that this condition may be a useful
therapeutic target for such treatments. Preclinical studies with
agents such as FT-11 have demonstrated improvements in a
diabetic model of HFPEF (Ren-2, streptozotocin).16
To our knowledge, this study is the first published analysis
of the relationship between peripheral collagen markers and
major cardiovascular outcomes in patients with HFPEF. A
study by Rossi et al17 looked at the relationship of collagen
turnover markers, echocardiographic features of diastolic
dysfunction, and survival in a cohort of 106 patients. How-
ever, unlike the present study of carefully delineated patients
with HFPEF, the Rossi study patients had mean ejection
fractions of 25% to 36% across the groups studied.
There are a number of caveats to the present study. The
first is that it is a relatively small subpopulation of the overall
I-PRESERVE study. However, patients appear to be ex-
tremely well matched in comparison with both the entire
study group and the placebo and irbesartan arms of the
substudy itself. Next, there are a number of organ-specific
contributors to plasma levels of these collagen markers, not
just the heart. In particular, bone18 and liver19 also are
important contributors, thus potentially confounding the re-
sults of this analysis. However, we did not specifically
exclude patients with liver and bone disorders because we
wanted to test the utility of these markers clinically in an
HFPEF population, irrespective of influencing comorbidities.
Finally, the collagen markers measured were not indepen-
dently predictive of future events by multivariable analysis,
limiting the interpretability of the results obtained. Indeed, in
some (but not all) cases, the HR for future events reverses on
multivariable analysis. Moreover, the inclusion of large
number of variables in the multivariable analysis for a
relatively small number of events could have led to overfit-
ting of the model. Hence, the results of the multivariable
analyses, especially for the secondary end points should be
interpreted with caution.
Despite these caveats, elevated baseline collagen markers
were found to be associated with future major cardiovascular
events in an HFPEF population on univariable (but not
multivariable) analysis. Overall, these findings provide some
support to hypothesis that pathological fibrosis in the heart,
and possibly the peripheral vasculature, is contributory to
adverse clinical outcomes in patients with HFPEF.
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CLINICAL PERSPECTIVE
Heart failure with preserved ejection fraction (HFPEF) still is a poorly understood condition with no proven evidence-based
effective therapy despite its large public health impact. Understanding the pathophysiology of this condition, therefore, is
critical to develop specifically focused treatment strategies. The findings of the present study indicate that plasma levels
of collagen turnover markers are predictive of future events in the HFPEF population (albeit nonsignificantly so when
adjusted for other variables) and that 6 months of angiotensin receptor blockade is insufficient to meaningfully reduce
levels of these markers. These substudy findings with irbesartan were consistent with the neutral results of the
I-PRESERVE (Irbesartan in Heart Failure With Preserved Systolic Function) study overall. The clinical implication of
these findings is that if fibrosis and its sequelae are presumed to be important drivers of the disease process of HFPEF at
the cellular level as well as contributory to future major cardiovascular events, then more specifically targeted blockade
of fibrosis and its consequences is required. These targeted therapies may be through specific antifibrotic drugs as well as
use of existing or novel agents that act at least in part through potent antifibrotic actions. Furthermore, in evaluating the
clinical utility of therapies in HFPEF, assessment of the effect of these agents on fibrotic status of the heart may be
mechanistically revealing.
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